stockrowiRhythm Holdings, Inc.
IRTC Healthcare Medical Devices
iRhythm Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $747.1 million, up 26.2% from fiscal 2024.
- Revenue
- +14.9%
- EPS
- −462.5%
- Free cash flow
- −157.6%
- Total debt
- +0.48%
Quarter to September 2026, against a year earlier
Follow IRTC
Alert me
iRhythm Holdings, Inc. (IRTC) Gross margin
iRhythm Holdings, Inc.'s gross margin over the twelve months to 30 September 2026 was 72.3%, up 1.7 percentage points from fiscal 2025 (70.6%). Over the past ten years it has ranged from 59.3% (fiscal 2015) to 75.5% (fiscal 2019); the current reading is higher than 64% of that period. That is above the Medical Devices industry median of 57.8% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 70.6% | 1.71 |
| FY2024 | 68.9% | 1.51 |
| FY2023 | 67.4% | (1.19) |
| FY2022 | 68.5% | 2.38 |
| FY2021 | 66.2% | (7.34) |
| FY2020 | 73.5% | (2.04) |
| FY2019 | 75.5% | 1.88 |
| FY2018 | 73.7% | 2.11 |
| FY2017 | 71.6% | 4.14 |
| FY2016 | 67.4% | 8.09 |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 74.2% | 1.43 |
| Jun 2026 | 72.8% | 1.91 |
| Mar 2026 | 70.9% | 0.01 |
| Dec 2025 | 70.9% | (0.21) |
| 40 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| AXGN AxoGen, Inc. compare | 74.2% |
| IRTC iRhythm Holdings, Inc. | 72.3% |
| TXG 10x Genomics compare | 70.0% |
| LIVN LivaNova PLC compare | 67.8% |
| HAE Haemonetics Corporation compare | 59.6% |
| TMDX TransMedics Group, Inc. compare | 58.6% |
| NEOG Neogen Corporation compare | 47.4% |
| UFPT UFP Technologies, Inc. compare | 29.0% |
| ITGR Integer Holdings Corporation compare | 24.6% |
| Medical Devices industry median | 57.8% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on IRTC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement